Adolescent booster with hepatitis B virus vaccines decreases HBV infection in high-risk adults

Vaccine

Volumn 35, Issue 7, 2017, Pages 1064-1070

  Wang, Yuting ^a   Chen, Taoyang ^b   Lu, Ling ling ^b   Wang, Minjie ^a   Wang, Dongmei ^a   Yao, Hongyu ^b   Fan, Chunsun ^b   Qi, Jun ^a   Zhang, Yawei ^b,c   Qu, Chunfeng ^a  

^a CANCER HOSPITAL   (China)

^b QIDONG LIVER CANCER INSTITUTE   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent booster; Adulthood; Hepatitis B virus; Maternal HBsAg status; Vaccination

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; VIRUS DNA; RECOMBINANT VACCINE;

ADOLESCENT; ADULT; ADULTHOOD; ARTICLE; BLOOD SAMPLING; CHILD; CHILDHOOD; FEMALE; HEPATITIS B; HIGH RISK POPULATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MOTHER; PRIORITY JOURNAL; VACCINATION; BLOOD; CHRONIC HEPATITIS B; DRUG EFFECTS; HEPATITIS B VIRUS; IMMUNOLOGY; PATHOGENICITY; PRESCHOOL CHILD; PREVENTION AND CONTROL; PROCEDURES; SECONDARY IMMUNIZATION; VERTICAL TRANSMISSION; VIROLOGY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION, SECONDARY; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; VACCINATION; VACCINES, SYNTHETIC;

EID: 85008645123     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.12.062     Document Type: Article

References (42)

1. [1] Trépo, C., Chan, H.L., Lok, A., Hepatitis B virus infection. The Lancet 384 (2014), 2053–2063.
2. [2] Chen, D.S., Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 50 (2009), 805–816.
3. [3] Chiang, C.-J., Yang, Y.-W., You, S.-L., Lai, M.-S., Chen, C.-J., Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 310 (2013), 974–976.
4. [4] Qu, C., Chen, T., Fan, C., Zhan, Q., Wang, Y., Lu, J., et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med, 11, 2014, e1001774.
5. [5] Romano, L., Paladini, S., Van Damme, P., Zanetti, A.R., Update on hepatitis B disease: clinical and therapeutic aspects – reports from a topical meeting. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis 43 (2011), S2–S7.
6. [6] Lu, C.Y., Chiang, B.L., Chi, W.K., Chang, M.H., Ni, Y.H., Hsu, H.M., et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 40 (2004), 1415–1420.
7. [7] McMahon, B.J., Bruden, D.L., Petersen, K.M., Bulkow, L.R., Parkinson, A.J., Nainan, O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 142 (2005), 333–341.
8. [8] Zanetti, A.R., Mariano, A., Romano, L., D'Amelio, R., Chironna, M., Coppola, R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366 (2005), 1379–1384.
9. [9] Ni, Y.H., Huang, L.M., Chang, M.H., Yen, C.J., Lu, C.Y., You, S.L., et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 132 (2007), 1287–1293.
10. [10] Neaigus, A., Gyarmathy, V.A., Zhao, M., Miller, M., Friedman, S.R., Des Jarlais, D.C., Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis 195 (2007), 1052–1061.
11. [11] Lu, F.M., Li, T., Liu, S., Zhuang, H., Epidemiology and prevention of hepatitis B virus infection in China. J Viral Hepatitis 17 (2010), 4–9.
12. [12] Beasley, R.P., Hwang, L.Y., Lin, C.C., Ko, Y.C., Twu, S.J., Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol 117 (1983), 213–222.
13. [13] Chang, M.H., Hepatitis B virus infection. Semin Fetal Neonat Med 12 (2007), 160–167.
14. [14] Hyams, K.C., Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 20 (1995), 992–1000.
15. [15] Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. World Health Organization; 2015.
16. [16] Chen, H.L., Lin, L.H., Hu, F.C., Lee, J.T., Lin, W.T., Yang, Y.J., et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology, 142(773–81), 2012, e2.
17. [17] Lee, C., Gong, Y., Brok, J., Boxall, E.H., Gluud, C., Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332 (2006), 328–336.
18. [18] Milne, A., West, D.J., Chinh, D.V., Moyes, C.D., Poerschke, G., Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol 67 (2002), 327–333.
19. [19] Chen, M.L., A population-based study about risk factors of blood transmission of Hepatitis B virus. Med Inf (Chin) 29 (2016), 173–174.
20. [20] Chen, X., He, C., Xi, G.X., Zhang, J., Tian, L., Deng, X.Q., et al. Investigation of risk factors of blood donors infected with HBV and HCV. Mod Prev Med (Chin) 40 (2013), 2967–2971.
21. [21] Wu, J.S., Hwang, L.Y., Goodman, K.J., Beasley, R.P., Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 179 (1999), 1319–1325.
22. [22] Shahmoradi, S., Yahyapour, Y., Mahmoodi, M., Alavian, S.M., Fazeli, Z., Jazayeri, S.M., High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol 57 (2012), 515–521.
23. [23] Wu, T.W., Lin, H.H., Wang, L.Y., Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology 57 (2013), 37–45.
24. [24] Hong, M., Sandalova, E., Low, D., Gehring, A.J., Fieni, S., Amadei, B., et al. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun, 2015, 6.
25. [25] Xu, L., Wei, Y., Chen, T., Lu, J., Zhu, C.L., Ni, Z., et al. Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination. Vaccine 28 (2010), 5986–5992.
26. [26] Chinchai, T., Chirathaworn, C., Praianantathavorn, K., Theamboonlers, A., Hutagalung, Y., Hans, L.B.P., et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18–20 years after neonatal immunization. Viral Immunol 22 (2009), 125–130.
27. [27] Lu, C.Y., Ni, Y.H., Chiang, B.L., Chen, P.J., Chang, M.H., Chang, L.Y., et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15–18 years after neonatal immunization. J Infect Dis 197 (2008), 1419–1426.
28. [28] Sun, Z., Zhu, Y., Stjernsward, J., Hilleman, M., Collins, R., Zhen, Y., et al. Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detect Prev 15 (1991), 313–318.
29. [29] Allain, J.-P., Opare-Sem, O., Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroen Hepatol 13 (2016), 643–653.
30. [30] Pan, C.Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 374 (2016), 2324–2334.
31. [31] Hollinger, F.B., Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 48 (2008), 1001–1026.
32. [32] Rehermann, B., Ferrari, C., Pasquinelli, C., Chisari, F.V., The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2 (1996), 1104–1108.
33. [33] Sadeghi, A., Yahyapour, Y., Poortahmasebi, V., Shahmoradi, S., Roggendorf, M., Karimzadeh, H., et al. Clearance of HBV DNA in immunized children born to HBsAg-positive mothers, years after being diagnosed with occult HBV infection. J Viral Hepatitis 23 (2016), 282–285.
34. [34] Crotty, S., Follicular Helper CD4 T Cells (TFH). Annu Rev Immunol 29 (2011), 621–663.
35. [35] Lee, A.K., Ip, H.M., Wong, V.C., Mechanisms of maternal-fetal transmission of hepatitis B virus. J Infect Dis 138 (1978), 668–671.
36. [36] Lu, L.L., Chen, B.X., Wang, J., Wang, D., Ji, Y., Yi, H.G., et al. Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women. Int J Infect Dis 28 (2014), 41–44.
37. [37] Starr, T.K., Jameson, S.C., Hogquist, K.A., Positive and negative selection of T cells. Annu Rev Immunol 21 (2003), 139–176.
38. [38] McHeyzer-Williams, M., Davis, M., Antigen-specific development of primary and memory T cells in vivo. Science 268 (1995), 106–111.
39. [39] McHeyzer-Williams, L.J., Panus, J.F., Mikszta, J.A., McHeyzer-Williams, M.G., Evolution of antigen-specific T cell receptors in vivo: preimmune and antigen-driven selection of preferred complementarity-determining region 3 (CDR3) motifs. J Exp Med 189 (1999), 1823–1838.
40. [40] Fazilleau, N., McHeyzer-Williams, L.J., Rosen, H., McHeyzer-Williams, M.G., The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat Immunol 10 (2009), 375–384.
41. [41] Raimondo, G., Allain, J.-P., Brunetto, M.R., Buendia, M.-A., Chen, D.-S., Colombo, M., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49 (2008), 652–657.
42. [42] But, D.Y., Lai, C.L., Lim, W.L., Fung, J., Wong, D.K., Yuen, M.F., Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 26 (2008), 6587–6591.